Drug Profile
FX 125L
Alternative Names: FX125LLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Funxional Therapeutics
- Developer Funxional Therapeutics; STX Pharma
- Class Small molecules
- Mechanism of Action Chemokine inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Asthma; Inflammation
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in USA (PO)
- 01 Jan 2015 STX Pharma completed a phase-II clinical trial in Asthma in United Kingdom (PO) (EudraCT2014-002052-84)
- 24 Jul 2014 Phase-II clinical trials in Asthma in United Kingdom (PO)